Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions

• Váldodahkkit: Philippe Moris (Dahkki), Kristen M. Bauer (Dahkki), Jeffrey R. Currier (Dahkki), Heather Friberg (Dahkki), Kenneth H. Eckels (Dahkki), Ines O. Esquilin (Dahkki), Robert V. Gibbons (Dahkki), Bruce L. Innis (Dahkki), Richard G. Jarman (Dahkki), Sriluck Simasathien (Dahkki), Peifang Sun (Dahkki), Stephen J. Thomas (Dahkki), Veerachai Watanaveeradej (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2019-09-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Three phase II randomized trials evaluated the safety/immunogenicity of two formulations of live-attenuated tetravalent dengue virus (TDEN) vaccine in dengue-endemic (Puerto Rico, Thailand) and non-endemic (US) regions (NCT00350337/NCT00370682/NCT00468858). We describe cell-mediated immune (CMI) res...